Literature DB >> 31069702

Inflammation, Monoclonal Antibodies and Depression: Joining the Dots.

David Hunt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31069702     DOI： 10.1007/s40264-019-00819-0

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  12 in total

1.  New plaque psoriasis approval carries suicide warning.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2017-03-01       Impact factor: 84.694

2.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

3.  Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Authors:  D J Wallace; S Navarra; M A Petri; A Gallacher; M Thomas; R Furie; R A Levy; R F van Vollenhoven; S Cooper; Z J Zhong; W Freimuth; R Cervera
Journal:  Lupus       Date:  2012-12-04       Impact factor: 2.911

Review 4.  Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.

Authors:  Mark G Lebwohl; Kim A Papp; Lauren B Marangell; John Koo; Andrew Blauvelt; Melinda Gooderham; Jashin J Wu; Shipra Rastogi; Susan Harris; Radhakrishnan Pillai; Robert J Israel
Journal:  J Am Acad Dermatol       Date:  2017-10-03       Impact factor: 11.527

Review 5.  Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment.

Authors:  Laura A Lucaciu; Dan L Dumitrascu
Journal:  Ann Gastroenterol       Date:  2015 Oct-Dec

6.  Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis.

Authors:  Annett Kunkel; Martin Fischer; Judith Faiss; Doreen Dähne; Wolfgang Köhler; Jürgen H Faiss
Journal:  Front Neurol       Date:  2015-05-11       Impact factor: 4.003

Review 7.  The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.

Authors:  Ruth Ann Marrie; Stephen Reingold; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Gary Cutter; Nadia Reider
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

8.  Replicable and Coupled Changes in Innate and Adaptive Immune Gene Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive Disorder.

Authors:  Gwenaël G R Leday; Petra E Vértes; Sylvia Richardson; Jonathan R Greene; Tim Regan; Shahid Khan; Robbie Henderson; Tom C Freeman; Carmine M Pariante; Neil A Harrison; V Hugh Perry; Wayne C Drevets; Gayle M Wittenberg; Edward T Bullmore
Journal:  Biol Psychiatry       Date:  2017-07-06       Impact factor: 13.382

9.  Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.

Authors:  Martin Schaefer; Lucile Capuron; Astrid Friebe; Crisanto Diez-Quevedo; Geert Robaeys; Sergio Neri; Graham R Foster; Achim Kautz; Daniel Forton; Carmine M Pariante
Journal:  J Hepatol       Date:  2012-08-07       Impact factor: 25.083

10.  A controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  David H Miller; Omar A Khan; William A Sheremata; Lance D Blumhardt; George P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.